Search

Your search keyword '"Belluardo,N."' showing total 13 results
Start Over Author "Belluardo,N." Publisher elsevier ltd
13 results on '"Belluardo,N."'

3. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

Author

Macaluso, F.S., Cappello, M., Busacca, A., Fries, W., Viola, A., Costantino, G., Magnano, A., Vinci, E., Ferracane, C., Privitera, A.C., Piccillo, G., Belluardo, N., Giangreco, E., Romano, C., Citrano, M., Graziano, F., Garufi, S., Bertolami, C., Ventimiglia, M., Scrivo, B., Renna, S., Rizzuto, G., Casà, A., and Orlando, A.

Published
2021
Full Text
View/download PDF

5. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2

Author

Macaluso, F.S., Fries, W., Viola, A., Centritto, A., Cappello, M., Giuffrida, E., Privitera, A.C., Piccillo, G., Magnano, A., Vinci, E., Vassallo, R., Trovatello, A., Belluardo, N., Giangreco, E., Camilleri, S., Garufi, S., Bertolami, C., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Grova, M., and Orlando, A.

Published
2020
Full Text
View/download PDF

6. PC.01.2 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Author

Macaluso, F.S., Ventimiglia, M., Fries, W., Viola, A., Sitibondo, A., Cappello, M., Scrivo, B., Busacca, A., Privitera, A.C., Camilleri, S., Garufi, S., Di Mitri, R., Mocciaro, F., Belluardo, N., Giangreco, E., Bertolami, C., Renna, S., Orlando, R., Rizzuto, G., Cottone, M., and Orlando, A.

Published
2020
Full Text
View/download PDF

7. P.07.1 ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Author

Porcari, S., Fidanza, O., Alibrandi, A., Renna, S., Cappello, M., Siringo, S., Privitera, A.C., Inserra, G., Mocciaro, F., Magrì, G., Carroccio, A., Belluardo, N., Bertolami, C., Garufi, S., Ventimiglia, M., Macaluso, F.S., Viola, A., Cottone, M., Orlando, A., and Fries, W.

Published
2019
Full Text
View/download PDF

9. OC.02.4 THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD): A COMPARISON OF THE EFFICACY OF CURRENT BIOLOGICS IN CROHN'S DISEASE

Author

Orlando, A., Macaluso, F.S., Fries, W., Privitera, A.C., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, A., Carroccio, A., Genova, S., Bertolami, C., Vassallo, R., Romano, C., Pellegrino, S., Citrano, M., Accomando, S., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Ferracane, C., and Cottone, M.

Published
2018
Full Text
View/download PDF

10. OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety

Author

Orlando, A., Fries, W., Privitera, A., Cappello, M., Siringo, S., Inserra, G., Magnano, A., Di Mitri, R., Belluardo, N., Scarpulla, G., Magrì, G., Trovatello, A., Carroccio, A., Genova, S., Calandruccio, G., Vassallo, R., Romano, C., Magazzù, G., Citrano, M., Accomando, S., Ventimiglia, M., Renna, S., Orlando, R., Rizzuto, G., Vinci, E., Macaluso, F.S., and Cottone, M.

Published
2017
Full Text
View/download PDF

13. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain

Author

V. Di Liberto, Natale Belluardo, Giuseppa Mudò, Alessandra Bonomo, Monica Frinchi, Di Liberto, V, Bonomo, A, Frinchi, M, Belluardo, N, and Mudo, G

Subjects
Male, medicine.medical_specialty, Time Factors, medicine.drug_class, Tropomyosin receptor kinase B, Biology, Receptors, Metabotropic Glutamate, Hippocampus, Settore BIO/09 - Fisiologia, Mice, Neurotrophic factors, Internal medicine, Excitatory Amino Acid Agonists, medicine, Animals, RNA, Messenger, Amino Acids, neurotrophic factor, Neurons, Brain-derived neurotrophic factor, Dose-Response Relationship, Drug, hippocampu, Brain-Derived Neurotrophic Factor, General Neuroscience, Glutamate receptor, Brain, LY379268, Bridged Bicyclo Compounds, Heterocyclic, Receptor antagonist, Up-Regulation, Mice, Inbred C57BL, Metabotropic receptor, Endocrinology, BDNF, Xanthenes, Metabotropic glutamate receptor, cerebral cortex, Metabotropic glutamate receptor 2, Excitatory Amino Acid Antagonists, mGlu2/3 receptor
Abstract

A number of in vitro and in vivo studies using selective agonists have indicated a neuroprotective role for group-II metabotropic glutamate (mGlu2/3) receptors in various models of neuronal injury. Although an interplay among neurotrophic factors and mGlu2/3 receptors signalling system has been suggested as possible mechanism involved on neuroprotection, at present poor information are available concerning the in vivo regulation by mGlu2/3 receptors activation of specific neurotrophic factors. By using in situ hybridization and western blotting methods the aim of present study was to analyse the potential regulatory role of selective mGluR2/3 agonist LY379268 treatment on brain derived neurotrophic factor (BDNF) expression in the mouse brain. The treatment with LY379268 evidenced a significant upregulation of BDNF mRNA levels in the cerebral cortex and in the hippocampal formation with a peak at 3 h from treatment and its disappearance already at 6 h from treatment. An analysis of dose-effect curve revealed that LY379268 may significantly enhance BDNF mRNA expression already at dose of 0.250 mg/kg b.w. The upregulation of BDNF mRNA expression was followed by a significant increase of BDNF protein levels at 24 h from LY379268 treatment. These effects of LY379268 treatment on BDNF expression were restricted to neuronal cells and were blocked by the new selective mGlu2/3 receptor antagonist LY341495, suggesting a receptor specificity. Taken together these findings suggest that several previous observed neuroprotective and trophic actions of mGluR2/3 agonists treatment may be mediated, at least in the cerebral cortex and hippocampal formation, by upregulation of BDNF expression.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results